Takeda

22.09.2023 – 16:16
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
mehr
16.11.2005 – 17:33
Takeda's ACTOS(R) (pioglitazone) Reduces Risk of Further Heart Attack by 28 Percent in Patients With Type-2 Diabetes
London, November 16 (ots/PRNewswire) - - For Non-US Media Only - PROactive Study Also Shows a 37 Percent Reduction in Acute Coronary Syndrome With ACTOS New results from secondary analyses of the landmark PROactive Study found that ACTOS(R) (pioglitazone) significantly reduced the occurrence of fatal ...
mehr
07.10.2005 – 01:03
The Lancet Publishes Groundbreaking Proactive Study Showing Type-2 Diabetes Treatment Significantly Reduces Risk of Non-Fatal Heart Attacks, Strokes and Deaths
London (ots/PRNewswire) - - Takeda's ACTOS(R) (pioglitazone HCl) on Top of Standard Treatment Demonstrates Significant Cardiovascular Benefits A study published in The Lancet today shows that Takeda's ACTOS(R) (pioglitazone HCl), an oral glucose lowering medication, significantly reduces the combined risk ...
mehr
12.09.2005 – 15:16
PROactive Study Shows Takeda's ACTOS(R) (pioglitazone HCl) Reduces Heart Attacks, Strokes and Deaths
Athens, Greece (ots/PRNewswire) - Landmark data from the PROactive Study, presented today at the 41st meeting of the European Association for the Study of Diabetes (EASD) demonstrated that ACTOS(R) (pioglitazone HCl) significantly reduces the combined risk of heart attacks, strokes and death by 16% in high risk ...
mehr

Takeda

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older

Takeda's ACTOS(R) (pioglitazone) Reduces Risk of Further Heart Attack by 28 Percent in Patients With Type-2 Diabetes

The Lancet Publishes Groundbreaking Proactive Study Showing Type-2 Diabetes Treatment Significantly Reduces Risk of Non-Fatal Heart Attacks, Strokes and Deaths

PROactive Study Shows Takeda's ACTOS(R) (pioglitazone HCl) Reduces Heart Attacks, Strokes and Deaths